ArticleBMC gastroenterology2005
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.
Article in BMC gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.British journal of cancer · 2018Trial
- A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2009Trial
- Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Current oncology (Toronto, Ont.) · 2022Review
- Review
- An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.Nature communications · 2022Article
- Primary sclerosing cholangitis and pancreatic cancer: A retrospective cohort study of United States veterans.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Article
- An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression.Cancer metastasis reviews · 2021Review
- Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma.Molecular and clinical oncology · 2020Article
- Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma.BioMed research international · 2020Article
- Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies.Critical reviews in therapeutic drug carrier systems · 2019Review
- Molecular Aberrations in Periampullary Carcinoma.Indian journal of surgical oncology · 2017Article
- Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK.Oncology reports · 2016Article
- The genetic classification of pancreatic neoplasia.Journal of gastroenterology · 2015Review
- Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.Molecular diagnosis & therapy · 2013Review
- Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers.Digestive diseases and sciences · 2012Article
- Prenatal arsenic exposure and DNA methylation in maternal and umbilical cord blood leukocytes.Environmental health perspectives · 2012Article
- Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine.International journal of molecular sciences · 2011Article
- Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification.Journal of biomedicine & biotechnology · 2011Article
- Phenotype and genotype of pancreatic cancer cell lines.Pancreas · 2010Review
- Expression and methylation pattern of p16 in neuroblastoma tumorigenesis.Pathology oncology research : POR · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell cycle inhibitor and tumor suppressor gene p16/MTS-1 has been reported to be altered in a variety of human tumors. The purpose of the study was to evaluate primary pancreatic ductal adenocarcinomas for potentially inactivating p16 alterations.
methodsWe investigated the status of p16 gene by polymerase chain reaction (PCR), nonradioisotopic single strand conformation polymorphism (SSCP), DNA sequencing and hypermethylation analysis in 25 primary resected ductal adenocarcinomas. In addition, we investigated p16 protein expression in these cases by immunohistochemistry (IHC) using a monoclonal antibody clone (MS-887-PO).
resultsOut of the 25 samples analyzed and compared to normal pancreatic control tissues, the overall frequency of p16 alterations was 80% (20/25). Aberrant promoter methylation was the most common mechanism of gene inactivation present in 52% (13/25) cases, followed by coding sequence mutations in 16% (4/25) cases and presumably homozygous deletion in 12% (3/25) cases. These genetic alterations correlated well with p16 protein expression as complete loss of p16 protein was found in 18 of 25 tumors (72%).
conclusionThese findings confirm that loss of p16 function could be involved in pancreatic cancer and may explain at least in part the aggressive behaviour of this tumor type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.